Provexis (NZCA) AI Stock Analysis

1 Followers

Provexis

(Frankfurt:NZCA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthThe 45.1% annual revenue increase shows stronger commercial scale and demand for the company’s products. If growth can be sustained, it may improve operating leverage, support broader market reach, and create a foundation for eventual profitability despite current losses.

Negative Factors

Persistent UnprofitabilityRevenue growth has not yet translated into economic profitability, as operating and net losses remain substantial and the net margin is deeply negative. Continued losses can consume shareholder value, limit internally funded investment, and make the path to sustainable earnings harder to establish.

Provexis (NZCA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 18.88M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -80.5
Beta (1Y): -11.09
Revenue Growth: -4.92%
EPS Growth: 0.00%
Country: Germany
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Provexis Business Overview & Revenue Model

Company Description

Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tom...

Provexis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:NZCA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:EAH	61Neutral	GBP 58.27M	26.63	2.55%	―	9.96%	29.72%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:STX	43Neutral	GBP 34.37M	-4.31	64.57%	―	36.19%	60.75%
GB:CHLL	38Underperform	GBP 836.68K	-0.00	233.76%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:NZCA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NZCA	Provexis plc	0.01	-0.00	-23.08%
GB:EAH	Eco Animal Health	86.00	-1.50	-1.71%
GB:CHLL	Chill Brands Group PLC	1.60	-8.65	-84.39%
GB:HELD	Mountfield Group plc	0.90	-0.05	-5.26%
GB:STX	Shield Therapeutics	3.20	-3.55	-52.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Provexis AI Stock Analysis